A method and application for inducing pancreatic islet organoids from human amniotic epithelial cells.
By combining multi-stage culture medium formulations and hormone inhibitors, the problem of unstable reproduction of pancreatic islets induced by human amniotic epithelial cells has been solved, achieving efficient generation of pancreatic organoids for the treatment of diabetes.
Patent Information
- Application Number
- CN202611619630.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-20
- Publication Date
- 2026-11-17
AI Technical Summary
The existing method for inducing pancreatic islets using human amniotic epithelial cells is difficult to reproduce stably and is subject to ethical controversies and tumorigenic risks, thus limiting its clinical application in the treatment of diabetes.
A multi-stage culture medium formulation was used, including a modified serum-free amplification medium for human amniotic epithelial cells and a combination of various specific hormones and inhibitors. Through stepwise culture, pancreatic islet organoids were formed, OCT4 expression and the efficiency of morphological endoderm differentiation were improved, and highly efficient insulin-secreting cells were generated.
Stable induction of human amniotic epithelial cells into pancreatic islet organoids was achieved, generating cells expressing mature islet-related genes, which can lower blood glucose in mice and treat diabetes.
Smart Images

Figure CN123107910A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of medical technology, specifically to a method and application for inducing the formation of pancreatic islet organoids from human amniotic epithelial cells. Background Technology
[0002] Diabetes is mainly divided into two categories: type 1 and type 2. Type 1 diabetes and some types 2 diabetes are characterized by insulin deficiency. For patients with insulin deficiency, the core treatment strategies are exogenous insulin replacement therapy and islet transplantation. Islet transplantation is considered the most effective treatment for patients with insufficient insulin secretion. Clinical research on islets of various origin, such as allogeneic islets, xenogeneic islets, gene-edited islets, and stem cell-induced islets, has been conducted in numerous research institutions worldwide.
[0003] Stem cells are known as "universal cells" in the medical field. They can differentiate into various functional cells or tissues and organs and then be transplanted into patients to treat related diseases. In 2006, existing technology reported a protocol for differentiating human embryonic stem cells into insulin-secreting cells. However, the cells obtained through this protocol are less capable of insulin secretion than normal islets. To improve differentiation efficiency, researchers conducted further studies, elucidating the key regulatory roles of DNA methylation modification and signaling pathways in the islet differentiation process. In recent years, the technical protocols for stem cell differentiation into islets have become increasingly sophisticated. Researchers divide the induction of islets into six core stages: the fixed endoderm stage, the primitive digestive tract stage, the pancreatic progenitor stage, the endocrine progenitor cell stage, the endocrine cell stage, and the mature islet stage.
[0004] However, the clinical translation of islet transplantation for diabetes treatment still faces numerous drawbacks, including ethical restrictions, difficulty in sourcing and preserving islets, incompatibility of transplanted cells with the body's microenvironment, tumorigenicity, long islet induction cycles, and enormous financial costs. These issues hinder the true clinical application of islet transplantation for diabetes treatment. Therefore, it is urgent to find a novel stem cell and islet induction method that is free from ethical controversies, non-tumorigenic, abundant in source, and directly applicable to clinical treatment.
[0005] Human amniotic epithelial cells differentiate from epiblast cells during the blastocyst stage, retaining key embryonic stem cell molecular markers SSEA4 and OCT4, and possessing the potential to differentiate into all three germ layers. These cells express HLA-G, HLA-ABC, and HLA-E, but do not express HLA-DR, exhibiting low immunogenicity and immunomodulatory properties. Subcutaneous implantation of human amniotic epithelial cells into mice does not result in a strong immune rejection response. Human amniotic epithelial cells are non-tumorigenic, ensuring their safety for clinical use. Current research reports that human amniotic epithelial cells demonstrate significant application potential in the treatment of corneal defects, burns, joint injuries, and cardiovascular diseases.
[0006] Human amniotic epithelial cells possess multi-lineage differentiation potential. Previous studies have reported that human amniotic epithelial cells can differentiate into endoderm lineages in vitro, further generating cells with insulin and glucagon secretion functions. However, researchers have pointed out that existing human amniotic epithelial cell-induced islet-like structures are difficult to reproduce in independent experiments, and have also suggested that low expression of PDX-1 is a key factor in the differentiation failure of human amniotic epithelial cells. In 2025, researchers discovered through gene editing that increasing METTL3 expression in human amniotic epithelial cells could initiate islet differentiation, but the resulting islets still differed from mature islets, and the experimental cells involved in gene editing posed a certain risk of tumorigenesis. These factors limit the clinical application of human amniotic epithelial cell-induced islet formation for diabetes treatment. Therefore, developing a stable method for inducing human amniotic epithelial cells to form islet organoids is crucial to solving the problem of human amniotic epithelial cell therapy for diabetes. Summary of the Invention
[0007] The purpose of this invention is to at least solve one of the technical problems existing in the prior art, and to provide a method and application for inducing the formation of pancreatic islet organoids by human amniotic epithelial cells.
[0008] The technical solution of the present invention is as follows: In a first aspect, the present invention provides a method for inducing the formation of pancreatic islet organoids from human amniotic epithelial cells, comprising the following steps: S1. Placental tissue is separated and digested to obtain human amniotic epithelial cells; S2. The human amniotic epithelial cells are initially cultured in a modified serum-free amplification medium for human amniotic epithelial cells to obtain human amniotic epithelial cells P0; the human amniotic epithelial cells P0 are amplified and cultured in the modified serum-free amplification medium for human amniotic epithelial cells until the 30th generation to obtain human amniotic epithelial cells P30. S3. Add the human amniotic epithelial cells P30 to the first culture medium and culture for 5-7 days; S4. After the culture is completed, add the second culture medium and continue to culture for 2-4 days; S5. After the culture is completed, add the third culture medium and continue to culture for 1 to 3 days; S6. After the culture is completed, add the fourth culture medium and continue to culture for 3-5 days; S7. After the culture is completed, add the fifth culture medium and continue to culture for 5-7 days; S8. After the culture is completed, the cells are made into a suspension using digestion solution, and the suspension is added to the sixth culture medium and cultured for 5 to 7 days. S9. After the culture is completed, add the seventh culture medium and continue to culture for 5-7 days to obtain pancreatic islet organoids; In S2, the modified serum-free amplification medium for human amniotic epithelial cells includes: DMEM / F12, B27 serum-free additive, serum substitute, additive containing L-alanyl-L-glutamine dipeptide, MEM NEAA, lithium chloride, nicotinamide, CHIR99021, ALK5 inhibitor, RAR agonist, SMO receptor agonist, NK inhibitor, histone methyltransferase DOT1L inhibitor, 3-deadenine A, EHMT2 inhibitor, JAK inhibitor, p38 MAPK inhibitor, CBP / p300 bromodomain inhibitor, compound VTP50469, AKT kinase inhibitor, vitamin C, A-ketoglutarate, fibroblast growth factor 2, EZM0414 TFA, DNMT1 selective inhibitor, cimetidine, 5-iodine tuberculin, A-485 and MOZ inhibitor; In S3, the first culture medium includes: DMEM / F12, B27 serum-free additive, serum substitute, additive containing L-alanyl-L-glutamine dipeptide, MEM NEAA, CHIR99021, MEK inhibitor, β-Raf kinase inhibitor, annexin A2 targeting activator, transphenylcyclopropane, valproic acid, EPZ5676, 3-deadenine A, ROCK inhibitor, vitamin C, and histidine-rich glycoprotein; In S4, the second culture medium includes: DMEM / F12, αMEM, an additive containing L-alanyl-L-glutamine dipeptide, CHIR99021, LDN193189, ROCK-2 inhibitor and vitamin C; In S5, the third culture medium includes: DMEM / F12, αMEM, an additive containing L-alanyl-L-glutamine dipeptide, vitamin C, fibroblast growth factor 7, PORCN inhibitor and TGF-β type I receptor inhibitor. In S6, the fourth culture medium includes: DMEM / F12, αMEM, B27 serum-free additive, additive containing L-alanyl-L-glutamine dipeptide, vitamin C, retinoic acid, Smo receptor antagonist, PORCN inhibitor and LDN193189. In S7, the fifth culture medium includes: DMEM, B27 serum-free additive, ALK5 inhibitor, BET inhibitor, fibroblast growth factor 18, fibroblast growth factor 2 and epidermal growth factor. In S8, the sixth culture medium includes: DMEM, B27 serum-free additive, additive containing L-alanyl-L-glutamine dipeptide, vitamin C, LDN193189, Smo receptor antagonist, adult neurogenesis promoter, triiodothyronine, heparin, γ-secretase inhibitor, ALK5 inhibitor, PORCN inhibitor and Y27632. In S9, the seventh culture medium includes: DMEM, B27 serum-free additive, vitamin C, triiodothyronine, heparin, ALK5 inhibitor, forscorin, N-acetyl-L-cysteine, zinc sulfate, and R428.
[0009] In a preferred embodiment of the present invention, in S2, the content of each component in the modified serum-free amplification medium for human amniotic epithelial cells is as follows: DMEM / F12 90% v / v, B27 serum-free additive 2% v / v, serum substitute 5% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, MEM NEAA 1% v / v, lithium chloride 5 mM, nicotinamide 1 mM, CHIR99021 3 μM, ALK5 inhibitor 10 μM, RAR agonist 2 μM, SMO receptor agonist 0.5 μM, NK inhibitor 1 μM, histone methyltransferase DOT1L inhibitor 2 μM, 3-deadenine A 2 μM, EHMT2 inhibitor 1 μM, JAK inhibitor 1 μM, p38 MAPK inhibitor 2 μM, CBP / p300 bromodomain inhibitor 1 μM, and compound VTP50469. The following were added: 0.5 μM AKT kinase inhibitor, 1 μM vitamin C, 250 μM α-ketoglutarate, 250 μM fibroblast growth factor, 250 ng / mL EZM0414TFA, 0.2 μM DNMT1 selective inhibitor, 1 μM cimetidine, 1 μM 5-iodine-1, 0.5 μM A-485 and 1 μM MOZ inhibitor; the culture conditions included: cultured on a substrate-coated culture plate at 37°C in a 5% CO2 incubator.
[0010] In a preferred embodiment of the present invention, in S3, the content of each component in the first culture medium is as follows: DMEM / F12 90% v / v, B27 serum-free additive 2% v / v, serum substitute 5% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, MEM NEAA 1% v / v, CHIR99021 1 μM, MEK inhibitor 1 μM, β-Raf kinase inhibitor 0.5 μM, annexin A2 targeting activator 10 μM, transphenylcyclopropane 10 μM, valproic acid 0.5 μM, EPZ5676 2 μM, 3-deadenine A 2 μM, ROCK inhibitor 10 μM, and vitamin C. The culture conditions included: 250 μM and histidine-rich glycoprotein 20 ng / mL; the culture conditions included: cultured on a matrix gel-coated plate at 37°C in a 5% CO2 incubator for 6 days; the culture medium was changed every 2 days; the first culture medium was added during the first culture medium change; the first culture medium without annexin A2 targeting activator, transphenylcyclopropane, EPZ5676, and 3-deadenine A was added during the second culture medium change; the first culture medium without annexin A2 targeting activator, transphenylcyclopropane, EPZ5676, 3-deadenine A, and valproic acid was added during the third culture medium change.
[0011] In a preferred embodiment of the present invention, in S4, the content of each component in the second culture medium is as follows: DMEM / F 1250% v / v, αMEM 48% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, CHIR99021 6 μM, LDN193189 100 nM, ROCK-2 inhibitor 50 nM, and vitamin C 250 μM; the culture conditions include: culture at 37°C in a 5% carbon dioxide constant temperature incubator for 3 days; the culture medium is changed daily, wherein the second culture medium is added during the first culture medium change; and the second culture medium without CHIR99021 is added during the second and third culture medium changes.
[0012] In a preferred embodiment of the present invention, in S5, the content of each component in the third culture medium is as follows: DMEM / F 1250% v / v, αMEM 48% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, vitamin C 250 μM, fibroblast growth factor 750 ng / mL, PORCN inhibitor 100 nM and TGF-β type I receptor inhibitor 1 μM; the culture conditions include: 37°C, 5% carbon dioxide constant temperature incubator for 2 days.
[0013] In a preferred embodiment of the present invention, in S6, the content of each component in the fourth culture medium is as follows: DMEM / F 1250% v / v, αMEM 48% v / v, B27 serum-free additive 1% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, vitamin C 250 μM, retinoic acid 2 μM, Smo receptor antagonist 0.25 μM, PORCN inhibitor 100 nM, and LDN193189 100 nM; the culture conditions include: 37°C, 5% CO2 constant temperature incubator for 4 days, with the culture medium changed every 2 days.
[0014] In a preferred embodiment of the present invention, in S7, the content of each component in the fifth culture medium is as follows: DMEM 98% v / v, B27 serum-free additive 1% v / v, ALK5 inhibitor 10 μM, BET inhibitor 1 μM, fibroblast growth factor 1810 ng / mL, fibroblast growth factor 2 10 ng / mL, and epidermal growth factor 50 ng / mL; the culture conditions include: cultured on a matrix gel-coated culture plate at 37°C in a 5% CO2 incubator for 6 days, with the culture medium changed every 2 days.
[0015] In a preferred embodiment of the present invention, in S8, the content of each component in the sixth culture medium is as follows: DMEM 98% v / v, B27 serum-free additive 1% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, vitamin C 250 μM, LDN193189 100 nM, Smo receptor antagonist 0.25 μM, adult neurogenesis promoter 10 μM, triiodothyronine 1 μM, heparin 10 μg / mL, γ-secretase inhibitor 0.1 μM, ALK5 inhibitor 10 μM, PORCN inhibitor 100 nM, and Y27632 10 μM; the culture conditions include: transferring the suspension to a microplate and culturing for 24 h to form spheres, then transferring the spheres to a low-adsorption plate shaker at 90 rpm, 37°C, and a 5% CO2 incubator for 6 days, changing the culture medium every two days.
[0016] In a preferred embodiment of the present invention, in S9, the content of each component in the seventh culture medium is as follows: DMEM 98% v / v, B27 serum-free additive 1% v / v, vitamin C 250 μM, triiodothyronine 1 μM, heparin 10 μg / mL, ALK5 inhibitor 10 μM, forscoringin 10 μM, N-acetyl-L-cysteine 2 mM, zinc sulfate 10 μM, and R428 0.5 μM; the culture conditions include: the low-adsorption culture plate is placed in a shaker at 90 rpm at 37°C and cultured in a 5% carbon dioxide constant temperature incubator for 6 days, with the culture medium changed every two days.
[0017] Secondly, the present invention provides a pancreatic islet organoid obtained by the method described above.
[0018] Thirdly, the present invention provides the application of the aforementioned pancreatic islet organoids in the preparation of products for treating diabetes.
[0019] This invention has at least one of the following beneficial effects: This invention provides a method for inducing the formation of pancreatic islet organoids from human amniotic epithelial cells. Using human amniotic epithelial cells as the initial culture medium, the method involves stepwise culture from stage 1 to stage 7, with different culture media used in each stage. These include a culture medium formulation that can rapidly increase the OCT4 expression level of human amniotic epithelial cells, a culture medium formulation that does not contain activin A and ensures cell survival while improving the differentiation efficiency of the endoderm (DE) stage, and an induction culture medium formulation that can efficiently expand pancreatic islet progenitor cells and ultimately generate pancreatic islet organoids to lower blood glucose in mice, thereby obtaining pancreatic islet organoids.
[0020] Tests have shown that the pancreatic organoids of this invention express mature pancreatic islet-related genes, can produce insulin, lower blood sugar in mice, and treat diabetes. Attached Figure Description
[0021] Figure 1 The results of the pluripotency induction experiment of human amniotic epithelial cells are shown. In the figure, A represents the expression of pluripotency genes in human amniotic epithelial cells under different culture conditions detected by RT-qPCR; B represents the expression of pluripotency proteins in human amniotic epithelial cells after 30th generation culture and amplification using stage 1 medium (P30 S1) detected by fluorescence. The scale bar is 200 μm.
[0022] Figure 2 This figure shows the experimental results of inducing human amniotic epithelial cells to differentiate into the morphological endoderm. Figure A shows the expression of human amniotic epithelial cells induced into morphological endoderm using existing experimental methods. Figure B compares the expression of SOX17 in hAECs HYDE (red curve) and hAECs P0 (blue curve). Figure C compares the expression of PDX-1 in hAECs HY Islet (red curve) and hAECs P0 (blue curve). Figure D shows the expression of FOXA2, SOX17, and GATA6 during morphological endoderm formation induced by different induction methods, detected by RT-qPCR. Figure E shows the expression of FOXA2 and SOX17 proteins during morphological endoderm formation induced by different induction methods, with a scale bar of 200 μm.
[0023] Figure 3This figure shows the proportions of pluripotent cells and type-2 endoderm cells during human amniotic epithelial cell culture, as well as the SOX17 expression in type-2 endoderm cells derived from human amniotic epithelial cells. In the figure, A represents the proportions of OCT4-positive pluripotent cells in hAECs P30, the proportions of SOX17-positive type-2 endoderm cells in human amniotic epithelial cells without stage one (hAECs P30 S2), the proportions of OCT4-positive pluripotent cells after stage one (hAECs P30 S1), and the proportions of SOX17-positive type-2 endoderm cells after stages one and two (hAECs P30 S1+S2). The red curve represents the control group hAECs P0, and the blue curves represent hAECs P30, hAECs P30 S2, hAECs P30 S1, and hAECs P30 S1+S2, respectively. Figure B shows the SOX17 expression in type-2 endoderm cells derived from human amniotic epithelial cells.
[0024] Figure 4 The figures show changes in cell morphology and the expression of pancreatic progenitor cell marker genes NKX6.1 and PDX-1 during the formation of pancreatic islet organoids, with a scale bar of 500 μm. In the figures, A represents changes in cell morphology during the induction of pancreatic islet organoids from human amniotic epithelial cells; B represents the expression of pancreatic progenitor cell marker genes NKX6.1 and PDX-1 in the hAECs, PP, PPEXP P20 I, and PPEXP P20 I+F groups; and C shows the proportion of pancreatic progenitor cells with double positivity for NKX6.1 and PDX-1 proteins in the final pancreatic progenitor cells produced by the hAECs, PP, PPEXP P20 I, and PPEXP P20 I+F culture methods.
[0025] Figure 5 The expression of islet-related genes FOXA2, NKX2.2, NKX6.1, PDX-1, ARX, HHEX, SST, MAFA, INSULIN, NEUROD1, and GCG after human amniotic epithelial cells were induced to form islet organoids.
[0026] Figure 6The results are from mouse experiments. In the figures, A shows the process of establishing a diabetes model in NOD mice; B shows the expression of insulin and glucagon in the mouse pancreas before and after modeling (scale bar: 200 μm); C shows insulin granules in islets induced by human amniotic epithelial cells under transmission electron microscopy (scale bar: 2 μm); D shows the state two months after injection into the subcapsular region of the mouse kidneys (scale bar: 5000 μm); E shows the weekly changes in fasting blood glucose in mice after subcapsular transplantation of islets induced by human amniotic epithelial cells and kidneys; F shows the changes in blood glucose within 120 minutes after intraperitoneal injection of glucose in mice, as detected by the GTT experiment; and G shows the changes in glycated hemoglobin levels in mouse blood.
[0027] Figure 7 This is a flowchart illustrating the culture process for inducing pancreatic islet organoids from amniotic epithelial cells, as described in this invention. Detailed Implementation
[0028] To make the technical problems solved, the technical solutions, and the beneficial effects of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
[0029] The technical terminology involved in this invention is explained as follows: Human amniotic epithelial cells (hAECs). Definitive Endoderm (DE) Primitive gut tube stage (PG); Prostate phase of the pancreas (PF); Pancreatic endoderm and endocrine progenitor (PP) phase. Endocrine cell phase (hormone expressing endocrine, EN); Mature islet stage; Human amniotic epithelial cell-derived fixed endoderm (hAECs-DE). Human amniotic epithelial cell-derived pancreatic islets (hAECs-Islet).
[0030] The present invention will be further described in detail below with reference to specific embodiments, but the present invention is not limited to the following specific embodiments.
[0031] Example 1 A method for inducing the formation of pancreatic islet organoids from human amniotic epithelial cells includes the following steps: 1) Isolation and culture of human amniotic epithelial cells: Separation: Placental tissue was collected within 5 hours after cesarean section (the human placental tissue used in this study was provided by the Department of Obstetrics and Gynecology of the First Affiliated Hospital of Nanchang University, obtained from the donor of the cesarean section, and the donor had signed an informed consent form). The tissue was placed in DMEM / F12 culture solution, and the amnion layer was separated from the basement membrane layer using forceps. The tissue was then digested in a water bath at 37°C with 0.05% v / v trypsin for 1 hour. After 1 hour, the liquid was collected and centrifuged at 300 g / min for 10 minutes. The obtained human amniotic epithelial cells (hAECs) were resuspended in serum-free culture medium to obtain an hAEC cell suspension.
[0032] Culture: hAECs cell suspension was cultured at a rate of 5 mL of modified serum-free human amniotic epithelial cell amplification medium per 1 million human amniotic epithelial cells. The culture conditions were: substrate-coated culture plates, 37°C, 5% CO2 incubator. When the cells expanded to 80%, 4 mL of cell digestion solution (Accutase digestion solution, Wuhan Pronosei Life Science Technology Co., Ltd., PB180201) was added to each 10 cm culture dish for 5 minutes to obtain primary human amniotic epithelial cells (i.e., human amniotic epithelial cells P0, hAECs P0). The digestion solution was removed, and the cells were resuspended in modified serum-free human amniotic epithelial cell amplification medium. The hAECs P0 cells were seeded again at a ratio of 1:30 and passaged. After multiple passages, human amniotic epithelial cells cultured to the 30th generation (i.e., human amniotic epithelial cells P30, hAECs P30) were obtained.
[0033] Table 1. Modified serum-free amplification culture medium for human amniotic epithelial cells (2) Islet differentiation of human amniotic epithelial cells: Human amniotic epithelial cells (hAECs P30) cultured to passage 30 were then... Figure 7 The following culture media are added in the order listed below for culturing, and the specific method is as follows: Phase 1: Add 2 ml of culture medium (as shown in Table 2) to each well of a 12-well plate of human amniotic epithelial cells cultured to passage 30. Culture in a matrix-coated plate at 37°C in a 5% CO2 incubator. Change the medium every two days. The first medium change adds all the medium. The second medium change removes the annexin A2 targeting activator (Py-60), tranylcypromine, EPZ5676, and 3-deazaneplanocin A. The third medium change removes the annexin A2 targeting activator, tranylcypromine, EPZ5676, 3-deazaneplanocin A, and valproic acid. After 6 days of culture, OCT4, SOX2, and NANOG-positive pluripotent cells (human amniotic epithelial cells P30 S1, hAECs P30 S1) are obtained.
[0034] Table 2 Phase 1 (6 days) Phase 2: Add the culture medium to the cell culture plate induced in Stage 1 according to the following formula. Add 2 ml of culture medium to each well of the 6-well plate. Incubate the culture plate in a matrix gel-coated medium at 37°C and 5% CO2 for 3 days. Change the culture medium every day. Remove CHIR99021 from the culture medium during the second and third medium changes to obtain human amniotic epithelial cells (hAECs S1+S2) after Stage 2 culture.
[0035] Table 3 Phase 2 (3 days) Phase 3: Add the culture medium to the stage 2 induced cell culture plate according to the following formula. Add 2 ml of culture medium to each well of the 6-well plate. Incubate the culture plate in a matrix gel-coated incubator at 37°C and 5% CO2 for 2 days to obtain human amniotic epithelial cells after stage 3 culture.
[0036] Table 4. Phase 3 (2 days) Phase 4: Add the culture medium to the stage 3 induced cell culture plate according to the following formula. Add 2 ml of culture medium to each well of the 6-well plate. Incubate the culture plate in a matrix gel-coated incubator at 37°C and 5% CO2 for 4 days. Change the medium every 2 days to obtain human amniotic epithelial cells after stage 4 culture.
[0037] Table 5. Phase 4 (4 days) Phase 5: Add the culture medium to the cell culture plate induced in stage 4 according to the following formula. Add 2 ml of culture medium to each well of the 6-well plate. Incubate the culture plate in a matrix gel-coated incubator at 37°C and 5% CO2 for 6 days. Change the medium every 2 days to obtain human amniotic epithelial cells after stage 5 culture.
[0038] Table 6 Phase 5 (6 days) Phase 6: After Phase 5, the cells were digested with accutase solution to prepare a suspension. 1 mL of accutase solution was added to each well of a 6-well plate. After centrifugation at 1000 rpm for 3 minutes, the supernatant was removed, and 3 mL of the culture medium shown in Table 7 was added for resuspending. The resuspended cells were transferred to 6-well microplates (Aggre Well 400) and cultured for 24 hours until spheroidization. After spheroidization, the cells were transferred to low-adsorption plates and cultured on a shaker at 90 rpm in a 37°C, 5% CO2 incubator. The culture medium was changed every two days to obtain human amniotic epithelial cells (EN) after Phase 6 culture.
[0039] Table 7. Phase 6 (6 days) Phase 7: After stage 6, the culture medium shown below was added, with 3 ml of medium added to each well of a 6-well plate. The plates were then incubated at 37°C in a 5% CO2 incubator on a low-adsorption plate shaker at 90 rpm. The culture medium was changed every two days to obtain human amniotic epithelial cell-induced islets (hAECs-Islets).
[0040] Table 8. Phase 7 (6 days) (3) As a control, the following control groups were set up, and the culture methods for each control group are as follows: hAECs P0 S1 group: Human amniotic epithelial cells P0 were cultured directly in stage 1 without being expanded to the 30th generation in serum-free mode.
[0041] hAECs P30 S2 group: Human amniotic epithelial cells (hAECs P30) cultured to the 30th generation were directly added to the culture medium in stage 2 without going through stage 1 culture.
[0042] hAECs S1 A+C group: hAECs P30 S1, obtained by culturing human amniotic epithelial cells to passage 30 (hAECs P30) and undergoing stage 1 culture, was cultured in medium containing activin A as shown in Table 9. 2 ml of medium was added to each well of a 6-well plate and incubated at 37°C with 5% CO2 for 1 day. After 1 day, the medium was replaced with medium that had CHIR99021 removed and the plates were incubated at 37°C with 5% CO2 for another 2 days. The medium was changed daily for 2 days.
[0043] hAECs S1 C group: hAECs P30 S1, obtained by culturing human amniotic epithelial cells to passage 30 (hAECs P30) and undergoing stage 1 culture, was cultured in a medium without activin A as shown in Table 10. 2 ml of medium was added to each well of a 6-well plate and incubated at 37°C with 5% CO2 for 1 day. After 1 day, the medium was replaced with one free of CHIR99021 and cultured at 37°C with 5% CO2 for 2 days. The medium was changed daily for 2 days.
[0044] Table 9. Culture media containing Activin A Table 10. Culture media without Activin A (4) Preparation of diabetic animal models and detection of the therapeutic effect of human amniotic epithelial cells.
[0045] Diabetes model preparation: 12-week-old male CB17.Cg-PrkdcscidLystbg-J / Crl (SCID / NOD) mice weighing 23g-25g were selected and randomly divided into three groups: blank group (no treatment, Normal), control group (STZ modeling and transplantation of human amniotic epithelial cells, abbreviated as hAECs group), and experimental group (STZ modeling and transplantation of islets induced by human amniotic epithelial cells, abbreviated as hAECs-Islet group). Figure 6 Figure A shows the procedure for establishing a diabetic model in NOD mice. Modeling was initiated after confirming that NOD mice had normal fasting blood glucose levels (below 7.0 mM). NOD mice were fasted for 16 hours before modeling. After fasting, streptozotocin (STZ) solution (50 mg / kg) was injected intraperitoneally for 5 consecutive days. Blood glucose levels were measured after modeling, and mice with random blood glucose levels above 30.0 mM (or fasting blood glucose above 16.8 mM) were selected for treatment efficacy testing. After successful modeling, human amniotic epithelial cells and islets induced from human amniotic epithelial cells were transplanted into the subcapsular region of the NOD mice's kidneys. Fasting blood glucose levels were measured every 7 days after treatment.
[0046] (5) Experimental results: 1. The expression of pluripotency genes POU5F1, NANOG, and SOX2 was determined using RT-qPCR, and the expression of pluripotency proteins DAPI, SOX2, OCT4, NANOG, and E-cadherin was determined using cellular protein immunofluorescence assay.
[0047] Figure 1 Figure A shows the expression of pluripotency genes POU5F1, NANOG, and SOX2 in primary human amniotic epithelial cells (hAECs P0), primary human amniotic epithelial cells after stage 1 culture (hAECs P0 S1), serum-free expansion of human amniotic epithelial cells to passage 30 (hAECs P30), and human amniotic epithelial cells after stage 30 expansion and stage 1 culture (hAECs P30 S1). This figure demonstrates that serum-free expansion followed by stage 1 culture significantly increases the expression of pluripotency genes.
[0048] Figure 1 Figure B shows the expression of pluripotency proteins DAPI, SOX2, OCT4, NANOG, E-cadherin, and combinations thereof after human amniotic epithelial cells were expanded to the 30th generation and cultured in stage 1. This figure demonstrates that serum-free expansion followed by stage 1 culture significantly increases the expression of pluripotency genes.
[0049] 2. Determination of the expression of genes and proteins related to the endoderm cells, namely FOXA2 and SOX17, by means of RT-qPCR and immunofluorescence detection of cell proteins.
[0050] Figure 2 In section A, hAECs P0 refers to the primary human amniotic epithelial cells of this invention, and hAECs HY DE refers to the experimental protocol reported in the prior art (HOU Y, HUANG Q FAU - LIU T, LIU T FAU - GUO L, et al. Human amnionepithelial cells can be induced to differentiate into functional insulin-producing cells [J]. 1745-7270 (Electronic)) to induce human amniotic epithelial cells to differentiate into the morphological endoderm. The results showed that the expression of genes related to morphological endoderm cells, FOXA2 and SOX17, was not increased.
[0051] Figure 2In the diagram, the red curve represents the expression of the islet-related marker SOX17 in the experimental protocol reported in the prior art (HOU Y, HUANG Q FAU - LIU T, LIU T FAU - GUO L, et al. Human amnion epithelial cells can be induced to differentiate into functional insulin-producing cells [J]. 1745-7270 (Electronic)). The blue curve represents the expression of the islet-related marker SOX17 in the primary human amnion epithelial cells (hAECs P0) of this invention.
[0052] Figure 2 In the figure, C, hAECs HY Islet (red curve) represents the expression of the islet-related marker PDX-1 in human amniotic epithelial cells when induced to eventually form islets using the experimental protocol reported in the prior art (HOU Y, HUANG Q FAU - LIUT, LIU T FAU - GUO L, et al. Human amnion epithelial cells can be induced to differentiate into functional insulin-producing cells [J]. 1745-7270 (Electronic)). The blue curve represents the expression of the islet-related marker PDX-1 in the primary human amniotic epithelial cells hAECs P0 of this invention.
[0053] Figure 2 B and Figure 2The results in section C showed that, during the induction process of the existing technique (HOU Y, HUANG Q FAU-LIU T, LIUT FAU-GUO L, et al. Human amnion epithelial cells can be induced to differentiate into functional insulin-producing cells [J]. 1745-7270 (Electronic)), the expression of the endodermal marker SOX17 and the islet cell-associated protein PDX-1 was not increased. In other words, the existing technique (HOU Y, HUANG Q FAU-LIU T, LIU T FAU-GUO L, et al. Human amnion epithelial cells can be induced to differentiate into functional insulin-producing cells [J]. 1745-7270 (Electronic)) failed to generate SOX17-positive cells. This result is consistent with another existing technique (Balaji S, Zhou Y, Opara EC, et al. Combinations of Activin A or Nicotinamide with the The results reported in Pancreatic Transcription Factor PDX1 Support Differentiation of Human Amnion Epithelial Cells Toward a Pancreatic Lineage [J]. 2152-4998 (Electronic) are consistent with those reported in the study, namely that the direct use of culture medium containing Activin A and nicotinamide cannot convert human amnion epithelial cells into insulin-secreting cells, indicating that the conventional protocol cannot form well-defined endoderm cells and subsequent insulin-secreting cells.
[0054] Figure 2In the figure, D represents the differences in the expression of SOX17, FOXA2, and GATA6 proteins after induction in human amniotic epithelial cells cultured to passage 30 (hAECs P30), human amniotic epithelial cells cultured to passage 30 after stage 1 using an Activin A-induced endoderm-fixing protocol (hAECs S1 A+C), human amniotic epithelial cells cultured to passage 30 after stage 1 using an Activin A-free induction protocol (hAECs S1 C), and human amniotic epithelial cells cultured to passage 30 after stages 1 and 2 (hAECs S1+S2). This figure shows that the protocol provided by this invention can significantly enhance the expression of fixed endoderm genes.
[0055] Figure 2 E in the figure represents the differences in the expression of FOXA2 and SOX17 proteins after different induction methods in human amniotic epithelial cells. The results showed that hAECs S1 A+C had high induction efficiency but low cell survival, hAECs S1 C had high cell survival rate but low induction efficiency, and hAECs S1+S2 had high induction efficiency and high cell survival rate.
[0056] 3. The ratio of pluripotent proteins OCT4+ and SOX17 was determined by methods including flow cytometry and Western blotting.
[0057] Figure 3 Figure A shows the proportion of OCT4-positive cells in the pluripotent cells of hAECs P30, hAECs P30 S1, hAECs P30S2, and hAECs S1+S2 before the formation of the fixed endoderm and the proportion of SOX17-positive cells after the induction of the fixed endoderm during the culture of human amniotic epithelial cells. The results show that the proportion of OCT4-positive (OCT4+) human amniotic epithelial cells that have not undergone stage 1 induction is low, and the subsequent induction of SOX17-positive cells is poor. The proportion of OCT4-positive human amniotic epithelial cells that have undergone stage 1 induction is high, and the subsequent induction of SOX17-positive cells is strong.
[0058] Figure 3 Figure B shows the difference in SOX17 protein expression levels in human amniotic epithelial cells after induction at stages 1 and 2, with HepG2 as a positive control and human amniotic epithelial cells as a negative control (Control). The induction method proposed in this invention significantly increased the expression of SOX17 protein in the shaped endoderm cells.
[0059] 4. Measurement methods: Inverted white light microscope photography, RT-qPCR, and flow cytometry.
[0060] (1) Observe the changes in cell morphology during the induction of pancreatic islet organoids by human amniotic epithelial cells.
[0061] Figure 4 Figure A shows the changes in cell morphology during the induction of pancreatic islet organoids from human amniotic epithelial cells. hAECs represent human amniotic epithelial cells, hAECs S1+S2 represent cells cultured through stages 1-2, EN represents cells cultured through stages 1-6, and hAECs-Islet represents islets induced from human amniotic epithelial cells. This figure shows that the cells were in good condition during the induction process, with no obvious abnormalities.
[0062] (2) Pancreatic progenitor cells were induced using human amniotic epithelial cells. The induction method is as follows: hAECs group: Human amniotic epithelial cells cultured to the 30th generation (hAECs P30) were used.
[0063] PP group: Human amniotic epithelial cells (hAECs P30) cultured to the 30th generation were cultured in stages 1 to 5 to obtain pancreatic progenitor cells (PP group). The cells were not expanded.
[0064] PPEXP P20 Group I: Human amniotic epithelial cells (hAECs P30) cultured to the 30th generation were cultured in stages 1 to 5, and then cultured in stage 5 medium with FGF18 removed. The cells were cultured to the 20th generation to obtain PPEXP P20 Group I.
[0065] PPEXP P20 I+F group: Human amniotic epithelial cells (hAECs P30) cultured to the 30th generation were cultured in stages 1 to 5, and then the cells were cultured in stage 5 medium to continue culturing the cells to the 20th generation to obtain the PPEXP P20 I+F group.
[0066] Figure 4 Figure B shows the expression of pancreatic progenitor cells marker genes NKX6.1 and PDX-1 when pancreatic progenitor cells were directly induced from human amniotic epithelial cells, and when IBET was added to expand pancreatic progenitor cells to the 20th generation (PPEXP P20 I), and when IBET and FGF18 were added to expand pancreatic progenitor cells to P20 (PPEXP P20 I+F), the results showed that PPEXP P20 I+F could significantly enhance the expression of pancreatic progenitor cell marker genes.
[0067] Figure 4 The C in the figure shows the proportion of NKX6.1 and PDX-1 proteins double-positive in pancreatic progenitor cells produced by human amniotic epithelial cells, PP, PPEXP P20 I, and PPEXP P20 I+F culture methods. The results show that PPEXP P20 I+F can significantly enhance the proportion and number of pancreatic progenitor cells.
[0068] 5. Measurement method: RT-qPCR.
[0069] Figure 5 This study showed the expression of islet-related genes FOXA2, NKX2.2, NKX6.1, PDX-1, ARX, HHEX, SST, MAFA, INSULIN, NEUROD1, and GCG after human amniotic epithelial cells were induced to form islet organoids. The results showed that the expression of islet-related genes in human amniotic epithelial cell-induced islet organoids (hAECs-Islets) was significantly increased.
[0070] 6. Measurement methods: transmission electron microscopy, cell immunofluorescence, GTT, glycated hemoglobin detection, and inverted white light microscope photography.
[0071] Figure 6 Figure B shows the expression of insulin and glucagon in the pancreas of mice before and after modeling. After modeling, insulin-positive cells in the mice were completely ablated, indicating that the diabetes model was successfully established.
[0072] Figure 6 The C-shaped structure shows that insulin granules can be observed under transmission electron microscopy in pancreatic islet organoids derived from human amniotic epithelial cells induced to form insulin granules.
[0073] Figure 6 Figure D shows the state of islets induced from human amniotic epithelial cells injected into the subcapsular region of mice two months later. The results show that the transplanted cells can survive under the renal capsule of mice.
[0074] Figure 6 The E in the figure shows the changes in fasting blood glucose in mice after subcapsular transplantation of human amniotic epithelial cells and human amniotic epithelial cell-induced islets and kidneys. The results show that human amniotic epithelial cell-induced islets can significantly reduce blood glucose in NOD mice.
[0075] Figure 6 The F-value in the figure shows that islets induced by human amniotic epithelial cells in the GTT experiment can reduce blood glucose in mice in real time.
[0076] Figure 6 The G in the study showed that islets induced by human amniotic epithelial cells could reduce glycated hemoglobin levels in diabetic mice.
[0077] The above description is only a preferred embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any equivalent substitutions or modifications made by those skilled in the art within the scope of the technology disclosed in the present invention, based on the technical solution and inventive concept of the present invention, should be covered within the scope of protection of the present invention.
Claims
1. A method for inducing the formation of pancreatic islet organoids using human amniotic epithelial cells, characterized in that, Includes the following steps: S1. Placental tissue is separated and digested to obtain human amniotic epithelial cells; S2. The human amniotic epithelial cells are initially cultured in a modified serum-free amplification medium for human amniotic epithelial cells to obtain human amniotic epithelial cells P0; the human amniotic epithelial cells P0 are amplified and cultured in the modified serum-free amplification medium for human amniotic epithelial cells until the 30th generation to obtain human amniotic epithelial cells P30. S3. Add the human amniotic epithelial cells P30 to the first culture medium and culture for 5-7 days; S4. After the culture is completed, add the second culture medium and continue to culture for 2-4 days; S5. After the culture is completed, add the third culture medium and continue to culture for 1 to 3 days; S6. After the culture is completed, add the fourth culture medium and continue to culture for 3-5 days; S7. After the culture is completed, add the fifth culture medium and continue to culture for 5-7 days; S8. After the culture is completed, the cells are made into a suspension using digestion solution, and the suspension is added to the sixth culture medium and cultured for 5 to 7 days. S9. After the culture is completed, add the seventh culture medium and continue to culture for 5-7 days to obtain pancreatic islet organoids; In S2, the modified serum-free amplification medium for human amniotic epithelial cells includes: DMEM / F12, B27 serum-free additive, serum substitute, additive containing L-alanyl-L-glutamine dipeptide, MEM NEAA, lithium chloride, nicotinamide, CHIR99021, ALK5 inhibitor, RAR agonist, SMO receptor agonist, NK inhibitor, histone methyltransferase DOT1L inhibitor, 3-deadenine A, EHMT2 inhibitor, JAK inhibitor, p38 MAPK inhibitor, CBP / p300 bromodomain inhibitor, compound VTP50469, AKT kinase inhibitor, vitamin C, A-ketoglutarate, fibroblast growth factor 2, EZM0414 TFA, DNMT1 selective inhibitor, cimetidine, 5-iodine tuberculin, A-485 and MOZ inhibitor; In S3, the first culture medium includes: DMEM / F12, B27 serum-free additive, serum substitute, additive containing L-alanyl-L-glutamine dipeptide, MEM NEAA, CHIR99021, MEK inhibitor, β-Raf kinase inhibitor, annexin A2 targeting activator, transphenylcyclopropane, valproic acid, EPZ5676, 3-deadenine A, ROCK inhibitor, vitamin C, and histidine-rich glycoprotein; In S4, the second culture medium includes: DMEM / F12, αMEM, an additive containing L-alanyl-L-glutamine dipeptide, CHIR99021, LDN193189, ROCK-2 inhibitor and vitamin C; In S5, the third culture medium includes: DMEM / F12, αMEM, an additive containing L-alanyl-L-glutamine dipeptide, vitamin C, fibroblast growth factor 7, PORCN inhibitor and TGF-β type I receptor inhibitor. In S6, the fourth culture medium includes: DMEM / F12, αMEM, B27 serum-free additive, additive containing L-alanyl-L-glutamine dipeptide, vitamin C, retinoic acid, Smo receptor antagonist, PORCN inhibitor and LDN193189. In S7, the fifth culture medium includes: DMEM, B27 serum-free additive, ALK5 inhibitor, BET inhibitor, fibroblast growth factor 18, fibroblast growth factor 2 and epidermal growth factor. In S8, the sixth culture medium includes: DMEM, B27 serum-free additive, additive containing L-alanyl-L-glutamine dipeptide, vitamin C, LDN193189, Smo receptor antagonist, adult neurogenesis promoter, triiodothyronine, heparin, γ-secretase inhibitor, ALK5 inhibitor, PORCN inhibitor and Y27632. In S9, the seventh culture medium includes: DMEM, B27 serum-free additive, vitamin C, triiodothyronine, heparin, ALK5 inhibitor, forscorin, N-acetyl-L-cysteine, zinc sulfate, and R428.
2. The method according to claim 1, characterized in that, In S2, The components of the modified serum-free amplification medium for human amniotic epithelial cells were as follows: DMEM / F12 90% v / v, B27 serum-free additive 2% v / v, serum substitute 5% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, MEM NEAA 1% v / v, lithium chloride 5 mM, nicotinamide 1 mM, CHIR99021 3 μM, ALK5 inhibitor 10 μM, RAR agonist 2 μM, SMO receptor agonist 0.5 μM, NK inhibitor 1 μM, histone methyltransferase DOT1L inhibitor 2 μM, 3-deadenine A 2 μM, EHMT2 inhibitor 1 μM, JAK inhibitor 1 μM, p38 MAPK inhibitor 2 μM, CBP / p300 bromodomain inhibitor 1 μM, compound VTP50469 0.5 μM, AKT kinase inhibitor 1 μM, and vitamin C. 250 μM, A-ketoglutarate 250 μM, fibroblast growth factor 250 ng / mL, EZM0414 TFA 0.2 μM, DNMT1 selective inhibitor 0.03 μM, cimetidine 1 μM, 5-iodine tuberculin 1 μM, A-485 0.5 μM and MOZ inhibitor 1 μM; The culture conditions include: culture plates coated with matrix gel, cultured at 37°C in a 5% carbon dioxide constant temperature incubator.
3. The method according to claim 1, characterized in that, In S3 The contents of each component in the first culture medium are as follows: DMEM / F12 90% v / v, B27 serum-free additive 2% v / v, serum substitute 5% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, MEM NEAA 1% v / v, CHIR99021 1 μM, MEK inhibitor 1 μM, β-Raf kinase inhibitor 0.5 μM, annexin A2 targeting activator 10 μM, transphenylcyclopropane 10 μM, valproic acid 0.5 μM, EPZ5676 2 μM, 3-deadenine A 2 μM, ROCK inhibitor 10 μM, vitamin C 250 μM, and histidine-rich glycoprotein 20 ng / mL; The culture conditions included: culture in a substrate-coated culture plate at 37°C in a 5% CO2 incubator for 6 days; changing the culture medium every 2 days; adding the first culture medium during the first culture medium change; adding the first culture medium without annexin A2 targeting activator, transphenylcyclopropane, EPZ5676, and 3-deadenine A during the second culture medium change; and adding the first culture medium without annexin A2 targeting activator, transphenylcyclopropane, EPZ5676, 3-deadenine A, and valproic acid during the third culture medium change.
4. The method according to claim 1, characterized in that, In S4, The contents of each component in the second culture medium are as follows: DMEM / F12 50% v / v, αMEM 48% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, CHIR99021 6 μM, LDN193189 100 nM, ROCK-2 inhibitor 50 nM and vitamin C 250 μM; The culture conditions include: 37°C, 5% CO2 constant temperature incubator for 3 days; the culture medium is changed daily, with the second culture medium added during the first culture medium change; and the second culture medium without CHIR99021 added during the second and third culture medium changes.
5. The method according to claim 1, characterized in that, In S5, The contents of each component in the third culture medium are as follows: DMEM / F12 50% v / v, αMEM 48% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, vitamin C 250 μM, fibroblast growth factor 7 50 ng / mL, PORCN inhibitor 100 nM and TGF-β type I receptor inhibitor 1 μM; The culture conditions included: 37°C, 5% carbon dioxide constant temperature incubator for 2 days.
6. The method according to claim 1, characterized in that, In S6, The contents of each component in the fourth culture medium are as follows: DMEM / F12 50% v / v, αMEM 48% v / v, B27 serum-free additive 1% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, vitamin C 250 μM, retinoic acid 2 μM, Smo receptor antagonist 0.25 μM, PORCN inhibitor 100 nM, and LDN193189 100 nM; The culture conditions included: 37°C, 5% CO2 constant temperature incubator for 4 days, with the culture medium changed every 2 days.
7. The method according to claim 1, characterized in that, In S7 The contents of each component in the fifth culture medium are as follows: DMEM 98% v / v, B27 serum-free additive 1% v / v, ALK5 inhibitor 10 μM, BET inhibitor 1 μM, fibroblast growth factor 18 10 ng / mL, fibroblast growth factor 2 10 ng / mL and epidermal growth factor 50 ng / mL. The culture conditions included: culture plates coated with matrix gel, cultured at 37°C in a 5% CO2 constant temperature incubator for 6 days, with the culture medium changed every 2 days.
8. The method according to claim 1, characterized in that, In S8, the contents of each component in the sixth culture medium are as follows: DMEM 98% v / v, B27 serum-free additive 1% v / v, additive containing L-alanyl-L-glutamine dipeptide 1% v / v, vitamin C 250 μM, LDN193189 100 nM, Smo receptor antagonist 0.25 μM, adult neurogenesis promoter 10 μM, triiodothyronine 1 μM, heparin 10 μg / mL, γ-secretase inhibitor 0.1 μM, ALK5 inhibitor 10 μM, PORCN inhibitor 100 nM, and Y27632 10 μM. The culture conditions include: transferring the suspension to a microplate and culturing for 24 hours to form spheres, then transferring the spheres to a low-adsorption plate shaker at 90 rpm, 37°C, and a 5% CO2 incubator for 6 days, changing the culture medium every two days. In S9, the contents of each component in the seventh culture medium are as follows: DMEM 98% v / v, B27 serum-free additive 1% v / v, vitamin C 250 μM, triiodothyronine 1 μM, heparin 10 μg / mL, ALK5 inhibitor 10 μM, forscoringin 10 μM, N-acetyl-L-cysteine 2 mM, zinc sulfate 10 μM, and R428 0.5 μM; the culture conditions include: the low-adsorption culture plate is placed in a shaker at 90 rpm at 37°C and incubated in a 5% carbon dioxide constant temperature incubator for 6 days, with the culture medium changed every two days.
9. A pancreatic islet organoid, characterized in that, It is obtained by using the method described in any one of claims 1 to 8.
10. The use of the pancreatic islet organoids of claim 9 in the preparation of products for treating diabetes.
